The company had posted a consolidated net profit of Rs 19.7 crore in the previous financial year.
Dabur Pharmas consolidated revenues stood at Rs 278.30 crore for the fiscal year 2007-08 whereas the same was at Rs 326.70 crore in 2006-07.
The companys overall sales during 07-08 were lower than last year on account of the divesture of non-oncology business to Alembic in March 07.
However, on a like to like basis, the oncology business recorded a sales growth of over 11 per cent on a consolidated basis and five per cent on a standalone basis, the firm said in a filing to the Bombay Stock Exchange.
The year also saw a 30 per cent growth in oncology formulations business.
Commenting on the results, Dabur Pharmas CEO Ajay Kumar Vij said financial year 2007-08 has been a good year.
It was the first full year of operations as a pure oncology player and the focus has started yielding positive results which is clearly visible in the excellent oncology formulations growth, he added.
In late afternoon trade, shares of the firm were trading at Rs 73.05 on the BSE.